Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MABEL CTLs in EBV-Positive Lymphoma and Other Malignancies
NCT02287311Phase 1Active, not recruiting
- Sponsor
- Baylor College of Medicine
- Start
- Feb 2015
- Primary completion
- Jan 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of MABEL CTLs in Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), Mature T-cell and natural killer cell lymphoproliferative disorders (T/NK-LPD) and 4 more (3 arms), sponsored by Baylor College of Medicine. Primary endpoint: Number of Participants With a Dose-limiting Toxicity at 8 weeks. Started Feb 2015; status: active, not recruiting.
02
Drugs
MABEL CTLs
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)Mature T-cell and natural killer cell lymphoproliferative disorders (T/NK-LPD)chronic active Epstein-Barr virus infection (CAEBV)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02287311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02287311.